



Dynavax Technologies Corporation
Investor Relations Department
2929 Seventh Street
Berkeley, CA 94710
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: DVAX

| | |
|---------------|----------------------------|
| Last Trade: | 21.05 |
| Trade Time: | 4:00 PM ET Sep 25, 2017 |
| Change: | 0.55 (+2.683%) |
| Day Range | 20.40 - 21.45 |
| 52-Week Range | 3.20 - 21.85 |
| Volume | 1,486,108 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Dynavax is a clinical-stage immunology company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax is developing product candidates for use in m... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Sep 5, 2017*
[Dynavax to Present at Upcoming Investor Conferences](#)
- Aug 15, 2017*
[Dynavax Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock](#)
- Aug 9, 2017*
[Dynavax Prices Public Offering of Common Stock](#)
- Aug 8, 2017*
[Dynavax Announces Proposed Public Offering of Common Stock](#)
- Aug 3, 2017*
[Dynavax Provides U.S. Regulatory Update on HEPLISAV-B\(TM\) Following FDA Advisory Committee Meeting](#)

Upcoming Events [\[View all \]](#)

- Sep 27, 2017 4:00 PM ET*
[Cantor Fitzgerald Global Healthcare Conference](#)
- Financials** [\[View all \]](#)
 - [Second Quarter Financial Results](#)
- Mar 13, 2017*
[Annual Report \(10-K\)](#)
- Jul 10, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 7, 2017*
[Quarterly Report \(10-Q\)](#)
- May 8, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2016*
[Quarterly Report \(10-Q\)](#)